According to a recent retrospective analysis of prospectively collected data from patients with snakebite reported to the ToxIC North American Snakebite Registry, crotalidae immune F(ab’)2 (equine) was superior to crotalidae immune polyvalent Fab (ovine) in preventing what sequelae of North American rattlesnake envenomation?
Late hemotoxicity. These findings were consistent with the phase-3 trial and early clinical data from regional centers in Arizona and New Mexico. The low rate of late hemotoxicity, and the absence of clinically significant late hemotoxicity in this study serves as one piece of evidence to support reevaluation of the follow up policy in patients receiving only crotalidae immune F(ab’)2 (equine) in the proper clinical setting, though larger numbers may be needed before more universal policy changes.
Spyres MB, Padilla GK, Gerkin RD, et al. Late hemotoxicity following North American rattlesnake envenomation treated with crotalidae immune F(ab’)2 (equine) antivenom and crotalidae immune polyvalent Fab (ovine) antivenom reported to the North American Snakebite Sub-registry, Clinical Toxicology, 60:7, 838-842, DOI: 10.1080/15563650.2022.2042550